Neurocrine Biosciences shares traded lower (down roughly 3% to about $129) as the market continued to re-price the company after its most recent forward outlook, which included 2026 INGREZZA (valbenazine) net product sales guidance of $2.7–$2.8 billion. With no major same-day company press release surfacing in widely tracked filings and investor materials, the move looks primarily sentiment/positioning-driven rather than a single fresh headline catalyst. (sec.gov)

The stock’s recent trading has been sensitive to how investors interpret INGREZZA’s growth trajectory and 2026 spending cadence. Neurocrine’s filed earnings release lays out the 2026 sales range for INGREZZA and broader financial expectations, which can tighten the band of outcomes in models and drive incremental de-risking by short-term holders when the stock had previously priced in faster acceleration. (sec.gov)

NBIX has been active on the conference circuit in March 2026, which can amplify day-to-day trading as investors parse reiterated messaging versus any nuance on demand trends, competition, and pipeline timelines. Even when commentary is broadly consistent, high expectations can translate into “sell-the-news” pressure when there is no new upside catalyst. (seekingalpha.com)

Near-term attention remains on execution against the 2026 INGREZZA range, updates embedded in scheduled investor communications, and any additional disclosures in company investor materials. Investors will also watch for any new insider transaction filings or rating/target changes that can act as a spark for another leg in either direction. (neurocrine.com)